A REVIEW ON BULK MANUFACTURING IN THE PHARMACEUTICAL INDUSTRY
Muskan Shabbir Shaikh*, Sarang D. Kulkarni, Dr. P. N. Sable, Mrs. Sharda S. Kulkarni
ABSTRACT
Bulk pharmaceutical manufacturing, encompassing both active pharmaceutical ingredients (APIs) and large-scale drug product formulation, forms the foundation of the global healthcare supply chain. This review presents a structured overview of modern bulk manufacturing, including small-molecule chemical synthesis, biologics manufacturing, formulation unit operations, process scale-up, regulatory expectations, Quality by Design (QbD), Process Analytical Technology (PAT), Industry 4.0 solutions, sustainability, and supply-chain resilience. Traditional batch processing is compared with continuous manufacturing, with emphasis on technical advantages, implementation challenges, and quality-assurance implications. The review also highlights emerging manufacturing directions such as modular facilities, digital twins, mRNA platforms, and greener production systems. Overall, modern bulk manufacturing is moving from empirical, end-product testing models toward science-based, monitored, and digitally controlled systems that can improve process robustness, product quality, and patient access.
Keywords: Bulk manufacturing; Active Pharmaceutical Ingredient; Biologics; Continuous manufacturing; Quality by Design; Process Analytical Technology; Green chemistry; Industry 4.0.[1]
[Full Text Article]
[Download Certificate]